MaaT Pharma Q1 2026 Business Update and Financial Results
Decision brief
Answer first · skim in under a minute
MaaT Pharma has released its business update and financial results for Q1 2026, highlighting key regulatory developments and market implications.
Key questions this brief answers
- What financial results did MaaT Pharma report for Q1 2026?
- What is the regulatory status of MaaT013 (Xervyteg)?
- Which clinical programs did MaaT highlight in the Q1 update?
MaaT Pharma’s Q1 2026 update paired €0.8 million Early Access revenue and an €18.1 million cash position with a sharp regulatory signal: EMA’s CHMP conveyed a negative-trend view on MaaT013 (Xervyteg) ahead of a planned re-examination path.
Contents7 sections
Key Takeaways
- Cash stood at €18.1 million on 31 March 2026; April EIB Tranche B (€6 million) and cost actions extend runway into November 2026.
- Reported Q1 revenue was €0.8 million after the Early Access Program transition to Clinigen; like-for-like Xervyteg demand rose 19% year over year.
- CHMP signaled a negative trend on the MaaT013 MAA before the June 2026 formal vote; MaaT intends to request re-examination.
- EBMT 2026 featured ARES pivotal data for MaaT013 plus PHOEBUS, CHRONOS, and THRASSA presentations.
What did MaaT Pharma report for Q1 2026?
In a 26 May 2026 Business Wire release, Lyon-based MaaT Pharma (Euronext: MAAT) reported unaudited Q1 results and a pipeline update focused on Microbiome Ecosystem Therapies for cancer patients.
Cash and cash equivalents were €18.1 million at 31 March 2026, down from €24.9 million at year-end 2025, before counting the April drawdown of European Investment Bank Tranche B (€6 million). Management said cash measures plus that drawdown extend visibility into November 2026 versus August 2026 previously.
Q1 revenue was €0.8 million, versus €1.1 million of reported Early Access Program (EAP) revenue in Q1 2025. Since January 2026, MaaT sells product to Clinigen under licensing terms; on a like-for-like basis the company said Xervyteg-related revenues rose 19% year over year, underscoring continued hospital demand despite the accounting shift.
What is the CHMP outlook for MaaT013 (Xervyteg)?
As a post-period event, MaaT said that during an Oral Explanation with EMA’s Committee for Medicinal Products for Human Use (CHMP), it was informed of a “negative trend” ahead of the expected June 2026 formal vote on the Marketing Authorisation Application for MaaT013 in acute graft-versus-host disease (aGvHD).
Subject to that formal opinion, the company plans to request re-examination. U.S. development planning continues with limited near-term cash impact, contingent on funding and operational readiness. The EAP has treated roughly 230-plus patients across 13 countries, and U.S. expanded-access requests continue from major centers including City of Hope, Massachusetts General Hospital, and others named in the release.
For European BD and investors, the CHMP trend signal is the stock-defining near-term catalyst; cash runway through the re-examination window is the balance-sheet story that accompanies it.
Which clinical datasets were highlighted at EBMT 2026?
At EBMT 2026 in March, final ARES pivotal results for MaaT013 were presented in the presidential symposium. The company also presented PHOEBUS design and safety updates, CHRONOS real-world third-line GI-aGvHD outcomes (n=59; 29% 12-month overall survival and 37% Day-28 GI overall response with non-microbiome best available therapy), and THRASSA poster data.
CHRONOS data were published in April 2026 in Bone Marrow Transplantation, reinforcing unmet need in steroid-refractory GI-aGvHD. The Phase 2 PHOEBUS trial (NCT05762211) of oral MaaT033 in allogeneic hematopoietic cell transplantation remains ongoing, with one-year overall survival topline expected in Q4 2028 after repeated DSMB confirmations of a favorable safety profile.
ARES itself is registered as NCT04769895 for MaaT013 as salvage therapy in ruxolitinib-refractory GI-aGvHD, anchoring the European pivotal package that is now under CHMP re-examination risk.
How should investors and competitors read the update?
This is not a clean commercial-launch narrative. It is a financing-and-regulatory bridge: Clinigen EAP economics, EIB debt, and cost control buy time for a CHMP re-examination while PHOEBUS and next-generation MaaT034 (first-in-human targeted for 2027, funding dependent) keep the longer pipeline alive.
Competitors in aGvHD and microbiome therapeutics should watch whether re-examination restores a viable EU label path and whether U.S. trial initiation remains capital-constrained. Near-term calendar items listed by the company include the 16 June 2026 Annual General Meeting and 29 September 2026 H1 results.
Related NovaPharma coverage: European access initiatives, approval-to-access dynamics, and other CHMP opinion watch items.
Frequently Asked Questions
What financial results did MaaT Pharma report for Q1 2026?
On 26 May 2026, MaaT Pharma reported Q1 2026 revenues of €0.8 million from its Early Access Program and cash and cash equivalents of €18.1 million as of 31 March 2026, with runway extended into November 2026 after the April drawdown of EIB Tranche B (€6 million).
What is the regulatory status of MaaT013 (Xervyteg)?
In May 2026, MaaT Pharma said it was informed of a negative-trend opinion from EMA’s CHMP on its Marketing Authorisation Application for MaaT013 (Xervyteg) ahead of the expected June formal vote, and plans to request re-examination after the formal opinion.
Which clinical programs did MaaT highlight in the Q1 update?
The company highlighted pivotal ARES data for MaaT013 in acute graft-versus-host disease, the ongoing Phase 2 PHOEBUS trial of MaaT033 (NCT05762211) with topline overall survival expected in Q4 2028, and readiness work toward a first-in-human study of next-generation candidate MaaT034 in 2027 subject to funding.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
